Acumen Pharmaceuticals, Inc. ABOS
Set alert
At close · Oct 30
After hours · Oct 30, 7:59 PM ET
- YTD
- -90.04%
- 1 year
- -90.54%
- Open
- 0.3394
- Prev close
- 2.29
- Mkt cap
- 15.20M
- Vol
- 68.11M
- Avg vol
- 520.26K
- EPS
- -1.55
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.21
- High
- 0.352
- Forward P/E
- -1.17
- Beta
- 0.04
- Short ratio
- 6.61
- Inst. own
- 78.46%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 2.48
- 200-d avg
- 2.89
- 1y target
- 10.80
5D chart
Signals (78)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 29, 3:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:00 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| RSI: Overbought | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:25 PM | 6 days ago |
| RSI: Overbought | Oct 26, 3:05 PM | 6 days ago |
| RSI: Overbought | Oct 26, 2:40 PM | 6 days ago |
| RSI: Overbought | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:20 AM | 6 days ago |
News
2 days ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…
-
2 days ago benzinga.com
Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1
Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.
2 days ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
2 days ago benzinga.com
Nasdaq Down Over 600 Points; Amazon Shares Fall Following Weak Q3 Results
U.S. stocks fell Friday, with Nasdaq down 2.36% as Amazon missed Q3 estimates. Acumen plunged 85%, while oil rose 1.8% and gold fell 1.7%.
2 days ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
-
2 days ago benzinga.com
Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale…
2 days ago globenewswire.com
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer's Disease Rating Scale…
4 days ago seekingalpha.com
Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout
Acumen Pharmaceuticals is rated a speculative Buy ahead of November 2026 Phase 2 ALTITUDE-AD data for sabirnetug in early Alzheimer's disease. I estimate ABOS fair value at $2.57 per share, a 14%…
6 days ago seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
6 days ago marketbeat.com
Acumen Pharmaceuticals Q3 Earnings Call Highlights
Acumen Pharmaceuticals NASDAQ: ABOS said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble…
6 days ago benzinga.com
Acumen Pharmaceuticals Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals (NASDAQ:ABOS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
-
6 days ago benzinga.com
Acumen Pharmaceuticals Q3 EPS $(0.35) Beats $(0.37) Estimate
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 20.45 percent increase over losses…
6 days ago globenewswire.com
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026 IND filing for the Enhanced Brain…
-
1 week ago benzinga.com
Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of…
1 week ago globenewswire.com
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble…
1 week ago globenewswire.com
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that…
1 month ago zacks.com
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
1 month ago seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
-
1 month ago benzinga.com
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.
1 month ago globenewswire.com
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics…
1 month ago seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
2 months ago globenewswire.com
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble…
2 months ago defenseworld.net
ADAR1 Capital Management LLC Makes New Investment in Acumen Pharmaceuticals, Inc. $ABOS
ADAR1 Capital Management LLC acquired a new position in shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) during the second quarter, according to the company in its most recent filing with the…
2 months ago seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Acumen Pharmaceuticals Q2 Earnings Call Highlights
Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to…
2 months ago globenewswire.com
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that…
2 months ago globenewswire.com
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that…
3 months ago zacks.com
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
3 months ago zacks.com
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 months ago zacks.com
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
-
3 months ago benzinga.com
Acumen Announces New Findings Presented At AAIC 2026; JCR Collaboration Shows Improved Brain Penetration Of Anti‑Aβo Antibodies Via Transferrin Receptor Delivery In Mouse And Primate Models
EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device…
-
3 months ago benzinga.com
Acumen Pharmaceuticals To Present Data On Three Trials At Alzheimer's Association International Conference 2026
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of…
-
4 months ago benzinga.com
Acumen Pharmaceuticals Exercises Option For Development, Production, Commercialization Of Two Candidates To Treat Alzheimer's Disease Through JCR Pharmaceuticals' Blood-Brain Barrier -Penetrating Technology Platform J-Brain Cargo
JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen…
-
4 months ago benzinga.com
Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program For Alzheimer's Disease Treatments, IND Submission Expected In Mid-2027
ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR PharmaceuticalsEBD technology represents the only anti-amyloid…
-
5 months ago benzinga.com
Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
-
5 months ago benzinga.com
Acumen Pharmaceuticals Q1 EPS $(0.33) Beats $(0.36) Estimate
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 31.25 percent increase over losses…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
7 months ago benzinga.com
Acumen Pharmaceuticals Files Prospectus To Resell Up To 10,833,331 Shares From March 16, 2026 Private Placement
ACUMEN PHARMACEUTICALS, INC.Up to 10,833,331 shares of Common Stock This prospectus relates to the resale or other disposition from time to time by the selling stockholders identified in this
-
7 months ago benzinga.com
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.
-
7 months ago benzinga.com
Acumen Pharmaceuticals Q4 EPS $(0.41) Beats $(0.43) Estimate
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.43) by 5.09 percent. This is a 33.87 percent increase over losses…
-
7 months ago benzinga.com
Earnings Scheduled For March 26, 2026
Earnings Scheduled For March 26, 2026
-
7 months ago benzinga.com
Acumen Pharma Announces New Research Findings At International Conference On Alzheimer's And Parkinson's Diseases And Related Neurological Disorders
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's…
-
7 months ago benzinga.com
Market-Moving News for March 16th
NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated Capacity Across Multiple Locations Using NVIDIA Vera Rubin Platform Starting Early 2027 CTMX: 70%
-
7 months ago benzinga.com
Acumen Pharmaceuticals Announces Private Placement Of ~$35.75M At $3.30/Share
Proceeds from the financing are expected to primarily support Acumen's Enhanced Brain Delivery (EBD) program, including ongoing preclinical development work to support the nomination of a lead…
-
8 months ago benzinga.com
Acumen Shares New Alzheimer's Drug Data At Global Brain Disease Conference
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of…
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
9 months ago benzinga.com
Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
-
9 months ago benzinga.com
BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises the price target from $4 to $7.
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session